anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
After right heart catheterization,BPA procedures are performed via femoral vein approach. 8-Fr sheath is inserted into the vein and 6-Fr guiding cathater was advanced to the main pulmonary artery through the 8-Fr guiding catheter using a 0.035-inch wire. We select a branch of the pulmonary artery by a 6-Fr guiding catheter (JR4.0). Pulmonary angiography is performed manually using half contrast medium diluted with saline. A 0.014-inch guidewire (Sion) is crossed under the pulmonary angiography, and OCT (Fig.1: Types of lesions) is used for the detection of Lumen diameter (mm), Intimal thickness (mm), Intimal area (mm2), Intimal thickness/lumen diameter, Intimal area/lumen area, which are defined as short diameter assessed by OCT. The balloon size, the expansion pressure and the choice of scoring balloon or plain balloon angioplasty are at the discretion of the operator. Balloon-to-vessel (B/V) ratio is defined as the balloon diameter divided by vessel diameter assessed with OCT (1:0.7-1). Pulmonary arteries with an inner diameter of less than 4mm detected by OCT were selected for BPA performance. Scoring balloon and plain balloon are used in half of pulmonary lesions respectively., use the Plain balloon was used to predilate, If the vascular Lesion is a completely occlusive or the scoring balloon cannot pass through vessels.
FIELD: medicine. SUBSTANCE: invention can be used in anesthesiology, ophthalmology, stomatology, otorhinolaryngology and surgery. Agent comprises dicaine hydrochloride, sodium chloride and dicaine hydrochloride chemically bound with N-carboxymethylchitosan glycidylate as a polymeric carrier taken in the definite ratio of components. The ratio of dicaine hydrochloride to indicated polymeric carrier = 1.4:1, respectively. The novel agent shows the enhanced anesthetic effectiveness, prolonged effect, minimal irritating effect and low toxicity. EFFECT: enhanced effectiveness, valuable medicinal properties of agent. 4 tbl
This study will be conducted at pre-hospital emergency care (PHEC) facilities. The PHECs are medical units that are fully equipped and staffed to provide adequate emergency medical care to patients with PDIT. The study is designed to evaluate the safety and efficacy of Ryanodex in an on0site pre-hospital emergency setting where subjects are anticipated to be treated over a short period of time and then transferred to another medical facility or released. After screening and diagnosis of PDIT, SOC treatment will be initiated. Subjects eligible for the study will be randomized to either receive SOC + Ryanodex or to receive SOC only. Study subjects are expected to remain at the study site for a maximum of 6 hours post-baseline.
The rigorous experimental design includes a pilot study followed by a parallel-arm randomized control trial (RCT). The pilot will include approximately eight consenting members of the youth community advisory board (CAB) at each site location prior to the RCT. If a youth CAB does not currently exist at each site, one will be formed. Although the investigators have strong pilot data for the SYV intervention from Moshi, the pilot test proposed herein will help ensure recruitment, enrollment, intervention delivery, supervision, measurement technology and logistics run as expected at each site (Moshi, Mbeya, Mwanza, Ifakara). The pilot study will be comprised of 8 participants recruited at each site. Subsequently, for the RCT, we will individually randomize up to 750 participants to receive the SYV intervention or SOC (standard of care) to achieve 90% power to detect a 10 percentage point difference between arms in the primary outcome of virologic suppression at the two-tailed 5% significance level, accounting for clustering by SYV group in the intervention arm.

The intervention will be rolled out across four main sites, in four different Tanzanian regions, and in four waves separated in time by 6 months. There will be two SYV groups per wave at each site (\~8 groups per site) A study visit for all participants will be conducted baseline and approximately 4 months (T1), 6-, 12-, and 18-months post-baseline (T2, T3, T4) with 6-months post baseline being the primary endpoint. At 12 months post-baseline (T3), those randomized to the SYV intervention will receive a one-session SYV booster to improve content retention and study engagement as has been shown in prior studies.
The application provides a pharmaceutical which comprises a mutant non-retroviral virus (particularly HSV-1 and/or HSV-2) whose genome is defective in respect of a gene essential for the production of infectious virus. The virus can infect normal cells and undergo replication and expression of viral antigen genes in those cells but cannot produce normal infectious virus. The pharmaceutical is for prophylactic or therapeutic use in generating an immune response in a subject infected therewith. Where the non-retroviral virus is a herpes simplex virus e.g. HSV-1 or HSV-2, the defect can be in the glycoprotein gH gene. Vaccines and therapeutic pharmaceuticals are provided especially for epithelial, oral, vaginal and nasal administration. Also provided is use of a mutant based on HSV-1 for the preparation of a pharmaceutical for prophylactic or therapeutic use in generating an immune response in a subject against type-2 HSV infection.
The objective of the invention is to provide a pathogenic strain separated from tissue of Scophthalmus maximus with an edge-rot disease. The pathogenic strain is Vibrio anguillarum which is preserved in China General Microbiological Culture Collection Center, No. 3, Yard 1, West Beichen Road, Chaoyang District, Beijing on June 17th, 2013, with an accession number of CGMCC No. 7733. The screened Vibrio anguillarum is used for preparation of an inactivated vaccine. A preparation method for the inactivated vaccine for the Scophthalmus maximus edge-rot disease has the advantages of simple process, stable output, low cost and capacity of obtaining a great number of the inactivated vaccine with high immune effects. The inactivated vaccine prepared by using the preparation method has an immune protective rate of 68.5%, is a purely biological preparation, has the characteristics of safety and environment friendliness, does not generate drug residue, poses no pollution to the environment, fundamentally suppresses occurrence and prevalence of the Scophthalmus maximus edge-rot disease and provides technical support for large scale preparation of the inactivated vaccine for the Scophthalmus maximus edge-rot disease.
The invention discloses an immunomodulatory peptide Nc-CATH and application thereof. Belongs to the biomedical field. The immunoregulation peptide Nc-CATH is a cyclic polypeptide of which thirteenth cysteine and sixteenth cysteine form a pair of intramolecular disulfide bonds and are encoded by a small rana chensinensis defensive peptide gene of a special species of China amphibian, the molecular weight is 2703.07 daltons, the isoelectric point is 4.47, and the amino acid sequence is shown as SEQ ID NO. 2. The gene for encoding the precursor of the rana yunnanensis immunomodulatory peptide Nc-CATH consists of 663 nucleotide sequences, wherein the nucleotide sequences are shown in SEQ ID NO. 1; wherein the 397-468 nucleotide is the coding gene of the mature rana yunnanensis immunoregulatory peptide Nc-CATH. The application of the Yunnan small slit frog immunoregulatory peptide Nc-CATH in preparing medicines for treating infectious diseases caused by methicillin-resistant staphylococcus aureus and carbapenem-resistant escherichia coli. The beneficial effects are that: has stronger regulation effect on main immune cells of a host, and can obviously resist methicillin-resistant staphylococcus aureus and carbapenem-resistant escherichia coli infection.
Chronotype is the temporal behavior of an organism. Social jetlag, fear of missing out (FoMO), and phubbing have received increasing attention recently and are closely related to sleep quality. This study aimed to explore the relationship between chronotype and these factors and their effects on sleep quality among medical students. The FoMO scale, phubbing behavior assessment scale, morning-evening questionnaire, Pittsburgh sleep quality index, social jetlag questionnaire, and online sociodemographic data form were filled out by 537 students participating in the study. The average age of participants was 21.34 ± 1.38 years; 43.2% were male, and 56.8% were female. The majority (66.7%) had an intermediate chronotype, 20.9% an evening type, and 12.5% a morning type. Evening chronotypes exhibited the highest levels of social jetlag, daily internet/phone use, and the poorest sleep quality and daily functioning. Women reported significantly higher levels of FoMO (p < 0.001), phubbing (p = 0.020), and daytime dysfunction (p = 0.005). Multiple regression analysis showed poor sleep quality was associated with high FoMO, high phubbing, high levels of social jetlag, and evening chronotype. Additionally, daytime dysfunction was associated with female gender, poor sleep quality, high FoMO, and high levels of phubbing (p < 0.001, F = 16.128, R2 = 0.221). These results suggest that individuals with an evening type may be susceptible to social interaction, social media use, and sleep patterns, which may negatively affect sleep quality. It has also been determined that females may be at greater risk for FoMO and phubbing. Evaluation of individuals' chronotypes will be an essential step in treating behavioral addictions such as social media, screen, and smartphone addiction.
NEW MATERIAL:A compound expressed by formula I (R<1> and R<2> are H, lower alkoxy, lower alkylthio, lower alkyl, lower alkoxycarbonyl, halogen, di-lower alkylamino, OH, CF3 or NO2; R is H, CH3 or C2H5). EXAMPLE:2-[2-(2-methylpropoxy)anilino]-1,6-dihydro-6-oxo-4-pyrimidine carboxylic acid. USE:Medicine. Remedy for ulcer exhibiting enhancing action for gastrointestinal membrane mucosa protection factor. PREPARATION:An N-phenylguanidine derivative expressed by formula II obtained by reaction of aniline derivative and cyanamide is reacted with acetylene dicarboxylic acid diesters in an inert solvent such as toluene at from about room temperature to boiling point of the solvent for 5-24hr to obtain a compound expressed by formula I for R is CH3 or C2H5. Then, resultant compound is hydrolyzed with alkali by normal method to afford the compound expressed by formula I for R is H.
Nitric Oxide study gas will be initiated at 5 ppm using the INOvent delivery system. The delivery system provides for masked delivery of the treatment gas. This dose will be used for a 21-day period or until extubation.
Extravasation of ELLENCE can result in severe local tissue injury manifesting as blistering, ulceration, and necrosis requiring wide excision of the affected area and skin grafting. Extravasation should be considered if a patient experiences a burning or stinging sensation or shows other evidence indicating peri-venous infiltration or extravasation; however, extravasation may be present in patients who do not experience a stinging or burning sensation or when blood return is present on aspiration of the infusion needle. 

Venous sclerosis may result from an injection into a small vessel or from repeated injections into the same vein. Administer ELLENCE slowly into the tubing of a freely running intravenous infusion. Patients receiving initial therapy at the recommended starting doses of 100–120 mg/m2 should have ELLENCE infused over 15–20 minutes. For patients who require lower ELLENCE starting doses due to organ dysfunction or who require modification of ELLENCE doses during therapy, the ELLENCE infusion time may be proportionally decreased, but should not be less than 3 minutes [see Dosage and Administration (2.3)]. If possible, avoid veins over joints or in extremities with compromised venous or lymphatic drainage. Facial flushing, as well as local erythematous streaking along the vein, may be indicative of excessively rapid administration. It may precede local phlebitis or thrombophlebitis.

Immediately terminate infusion and restart in another vein if a burning or stinging sensation indicates perivenous infiltration. Perivenous infiltration may occur without causing pain. If extravasation is suspected, immediately discontinue the intravenous injection or continuous intravenous infusion [see Dosage and Administration (2.3)]. Apply ice to the site intermittently for 15 minutes, 4 times a day for 3 days. If appropriate, administer dexrazoxane at the site of extravasation as soon as possible and within the first 6 hours after extravasation.
Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
A system and method for organizing, manipulating, and displaying worklists of patient studies (108) for access by medical personnel is provided (116, 118). The patient studies may include medical images and data related to medical images. In some embodiments, the worklists are easily customizable, to permit a wide range of tasks to be handled in the worklist system. Updated worklist information may be pushed (110) to the appropriate workstations or users (116, 118) in nearly real-time, as updates become available, reducing errors that may be caused by outdated information in worklists. In some embodiments, worklists contain overlapping information, which permits numerous users to see the information, even if it is not immediately relevant to their tasks. This increased scrutiny may help to reduce errors.
The purpose of this study is to test a new noninvasive topical cream, AIJP (Arnebia Indigo Jade Pearl), for treatment of precancerous anal lesions in order to prevent their progression to anal cancer. AIJP is a topical Chinese herbal cream that has been specifically designed to treat people with the cancer precursor lesions caused by human papillomavirus (HPV). In general, HPV infection is a key factor in development of cervical, anal and vulvar cancers. People with HIV are especially vulnerable to develop anal cancer associated with HPV. It is known that prior to development of anal cancer a person develops a precancerous condition known as a high-grade squamous intraepithelial lesion (HSIL). Treatment of the HSIL can prevent progression to anal cancer. Current therapies for HSIL and anal cancer are highly invasive. A new effective noninvasive topical therapy for precancerous HSIL could have a high impact on prevention of anal cancer.
Disclosed herein are oxygen generating compositions. More specifically, the oxygen generating compositions comprise potassium superoxide or sodium peroxide, a material for stabilizing the reactivity and oxidizing power of potassium superoxide or sodium peroxide, and optionally at least one selected from an oxidation catalyst of carbon monoxide, a material for improving the moldability and processability of the composition and a material for increasing initial carbon dioxide absorption rate. The oxygen generating compositions can be utilized in a wide range of applications. The material for stabilizing the reactivity and oxidizing power of potassium superoxide or sodium peroxide is selected from calcium hydroxide (Ca(OH) ), aluminum hydroxide (Al(OH) ), magnesium hydroxide (Mg(OH) ), barium hydroxide (Ba(OH) ), calcium carbonate (CaCO ), talc and clay. The oxidation catalyst of carbon monoxide is selected from copper oxide (CuO), manganese oxide (MnO) and a mixture thereof (hopcalite). The material for improving the moldability and processability of the oxygen generating compositions is selected from glass powder, glass fiber, ceramic fiber, steel wool, bentonite, kaolinite, sodium silicate and potassium silicate. Since the oxygen generating compositions have stabilized reactivity and oxidizing power, they can be used in household goods. In addition, since the oxygen generating compositions have a higher compressive strength than pure potassium superoxide or sodium peroxide, they can be processed into various shapes.
Participants with no more than one prior chemotherapy regimen for NSCLC received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort, up to 125 mg once daily was used in subsequent cohorts.
BACKGROUND: Fruits and vegetables (F&Vs) are vital components of healthy diets but may be restricted in chronic kidney disease (CKD) to avoid high-potassium intake. We previously generated F&V patterns for patients in the National Health and Nutrition Examination Survey (NHANES) and demonstrated an increased prevalence of the overall low-intake pattern in patients with CKD.
OBJECTIVE: To evaluate the association of F&V patterns (overall low intake, high unprocessed, moderate processed, and high ultraprocessed) with the risk of kidney failure and its composite with death.
METHODS: Adults in NHANES III with valid dietary data and longitudinal follow-up for kidney failure and death were included. F&V patterns were identified using 24-h dietary recalls and latent class analysis, yielding 4 patterns. Cox models were used to evaluate the prospective association between each pattern and hazard of kidney failure or a composite of kidney failure or death over ≤20 y. Models were adjusted for demographics and select comorbidities and weighted for the complex survey design. Secondary analyses evaluated serum carotenoids as objective biomarkers of F&V intake.
RESULTS: Among 16,726 eligible participants in NHANES III, F&V consumption consistent with the high-ultraprocessed pattern associated with the highest risk of kidney failure after demographic and comorbidity adjustment, but attenuated with adjustment for kidney function. The high unprocessed pattern associated with the lowest adjusted risk of death or kidney failure combined [hazard ratio (HR): 0.73; 95% confidence interval (CI): 0.65, 0.81 relative to overall low intake]. Higher-serum carotenoids were associated with a lower adjusted risk of death or kidney failure combined (HR: 0.57; 95% CI: 0.49, 0.65 for quartile 4 compared with quartile 1). Results were similar in patients with CKD at baseline.
CONCLUSIONS: Higher intake of unprocessed F&Vs was associated with better outcomes in the general population and patients with CKD. Results emphasize the need to safely improve F&V intake in CKD.
Exercise recommendations will be made to this group. Videos and photographs of weekly exercises prepared by the therapist will be sent online to the patient every Monday for 4 weeks, patients will be advised to repeat these exercises 4 days a week.
BACKGROUND: Lung ischemia/reperfusion injury (LIRI) is a common occurrence in clinical practice and represents a significant complication following pulmonary transplantation and various diseases. At the core of pulmonary ischemia/reperfusion injury lies sterile inflammation, where the innate immune response plays a pivotal role. This review aims to investigate recent advancements in comprehending the role of innate immunity in LIRI.
METHODS: A computer-based online search was performed using the PubMed database and Web of Science database for published articles concerning lung ischemia/reperfusion injury, cell death, damage-associated molecular pattern molecules (DAMPs), innate immune cells, innate immunity, inflammation.
RESULTS: During the process of lung ischemia/reperfusion, cellular injury even death can occur. When cells are injured or undergo cell death, endogenous ligands known as DAMPs are released. These molecules can be recognized and bound by pattern recognition receptors (PRRs), leading to the recruitment and activation of innate immune cells. Subsequently, a cascade of inflammatory responses is triggered, ultimately exacerbating pulmonary injury. These steps are complex and interrelated rather than being in a linear relationship. In recent years, significant progress has been made in understanding the immunological mechanisms of LIRI, involving novel types of cell death, the ability of receptors other than PRRs to recognize DAMPs, and a more detailed mechanism of action of innate immune cells in ischemia/reperfusion injury (IRI), laying the groundwork for the development of novel diagnostic and therapeutic approaches.
CONCLUSIONS: Various immune components of the innate immune system play critical roles in lung injury after ischemia/reperfusion. Preventing cell death and the release of DAMPs, interrupting DAMPs receptor interactions, disrupting intracellular inflammatory signaling pathways, and minimizing immune cell recruitment are essential for lung protection in LIRI.
Epigallocatechin gallate (EGCG), a prominent bioactive compound found in tea, offers numerous health benefits. Previous studies have highlighted its potential in mitigating hyperuricemia. In this study, hyperuricemic mice induced by potassium oxonate (PO) were treated with EGCG or the anti-hyperuricemia medication allopurinol (AP) to investigate the mechanisms underlying their anti-hyperuricemic effects. The results demonstrated that both EGCG and AP significantly reduced serum uric acid (UA) levels. Further analysis revealed that EGCG promoted the expression of UA secretion transporter genes (Oat1 and Oct1) while inhibiting the expression of UA reabsorption transporter genes (Urat1 and Glut9) in the kidney. By 16S rDNA sequencing, EGCG, but not AP, was found to alter the composition of the gut microbiota. Notably, EGCG induced significant changes in the relative abundance of specific bacteria such as Lactobacillus, Faecalibaculum, and Bifidobacterium, which displayed high correlations with serum UA levels and UA-related gene expression. Metabolomic analysis suggested that EGCG-induced modifications in bacterial metabolites might contribute to the alleviation of hyperuricemia. Transcriptomic analysis of the intestinal epithelium identifies 191 differentially expressed genes (DEGs) in EGCG-treated mice, including 8 purine-related genes. This study elucidates the anti-hyperuricemic mechanisms of EGCG, particularly its influence on the gut microbiota and gene expression in the intestinal epithelium.
FIELD: medicine. SUBSTANCE: with blood myoglobulin rising to above 512 ng/ml, patient's peripheric vein is punctured, and apparatus for extracorporeal ultraviolet radiation of blood is connected, and using the roller pump of the apparatus, blood in the amount of 2 ml/kg is pumped through quartz cell at the rate of 16 ml/min above source of ultraviolet rays with wave length of 254 nm and collected into vessel with stabilizing solution. Then, collected blood is returned to patient through the same vein by subjecting the blood to repeated quartz lamp ultraviolet radiation. Procedures of blood extracorporeal radiation are repeated until the content of blood myoglobin is reduced down to 128 ng/ml. EFFECT: provided reduction of myoglobin in blood during period of early endotoxicosis and later without adverse effects on blood. 2 cl, 3 tbl
In this study, the cryotherapy interventions were based on previous studies, with the dominant hand wearing the frozen glove set as the experimental group, and the non-dominant hand that was not wearing a frozen glove as the control group. The Elasto-Gel flexible frozen glove (Southwest Technologies, North Kansas City, MO, USA) used in this study lasted for 20 to 40 minutes and was easy to clean.The cold temperature of the refrigerator was measured in advance to be -20.2°C to -22.8°C. The freezing of the gloves lasted for at least three hours, and the gloves were tested with an infrared temperature-measuring instrument before use.

Its temperature range was -24.3°C to -24.7°C. The patient began to wear gloves 15 minutes before the administration of paclitaxel for one hour, and replaced them with new frozen gloves at the 45th minute. The patient continued to wear the gloves until 15 minutes after the end of the chemotherapy drug administration, for a total of 90 minutes. These intervention procedures were used for each treatment for 12 weeks.